Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention

Vascular Health and Risk Management

Volumn 4, Issue 1, 2008, Pages 67-73

  Cuspidi, Cesare ^a,b   Negri, Francesca ^b   Zanchetti, Alberto ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Policlinico di Monza   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiotensin II receptor blockers; Atrial fibrillation; Left ventricular hypertrophy

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INOSITOL TRISPHOSPHATE; IRBESARTAN; LOSARTAN; PHOSPHOLIPASE C; PLACEBO; REACTIVE OXYGEN METABOLITE; VALSARTAN;

BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMIC STRESS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; OBESITY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPLASMIC RETICULUM; SINUS RHYTHM; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 41549153780     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2008.04.01.67     Document Type: Review

References (47)

1. Campbell JE, Janicki JS, Weber KT. 1995. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol, 27:1545-60.
2. Choudhury A, Varughese G, Lip GYH. 2005. Targeting the renin angiotensin aldosterone system in atrial fibrillation: a shift from electrical to structural therapy? Exp Opin Pharmacother, 6:2193-207.
3. Cruickshank JM, Lewis J, Moore V, et al. 1992 Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens, 6:85-90.
4. Cuspidi C, Ambrosioni E, Mancia G, et al. 2002. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens, 20:1307-14.
5. Cuspidi C, Meani S, Fusi V, et al. 2004. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens, 22:1991-8.
6. Cuspidi C, Muiesan ML, Valagussa L, et al. 2002. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens, 20:2293-300.
7. Dahlof B, Pennert K, Hansson L. 1992. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens, 5:95-100.
8. Dahlof B. 2001. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens, 14:174-82.
9. Dahlof B, Zanchetti A, Diez J, et al. 2002. Effect of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens, 20:1855-64.
10. Devereux RB, Wachtell K, Gerdts E, et al. 2004. Prognostic significance of left ventricular mass changes during treatment of hypertension. JAMA, 292:2350-6.
11. Devereux RB, Dahlof B, Gerdts E, et al. 2004. Regression of hypertensive left ventricular hypertrophy by losartan compared to atenolol. Circulation, 110:1456-62.
12. Disertori M, Latini R, Maggioni AP, et al. 2006. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med, 7:29-38.
13. Ducharme A, Swedberg K, Pfeffer MA, et al. 2006. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J, 151:985-91.
14. Fogari R, Mugellini A, Destro M, et al. 2006. Losartan and prevention of atrial recurrence in hypertensive patients. J Cardiovasc Pharmacol, 47:46-50.
15. Healey JS, Baranchuck A, Crystal E, et al. 2005. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J Am Coll Cardiol, 45:1832-39
16. Hennersdorf MG, Strauer BE. 2001. Arterial hypertension and cardiac arrhythmias. J Hypertens, 19:167-77.
17. Kaschina E, Unger T. 2003. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press, 12:70-88.
18. Kannel WB, Wolf PA, Benjamin EJ, et al. 1998. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol, 82:2N-9N.
19. Klingbeil AU, Schneider M, Martus P, et al. 2003. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med, 115:41-6.
20. Koren MJ, Devereux RB, Casale PN, et al. 1991. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med, 114:345-52.
21. Leonetti G, Cuspidi C. 1995. Heart and vascular changes in hypertension. J Hypertens, 13(Suppl 2):S29-S34.
22. Levy G, Anderson KM, Savage DD, et al. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med, 322:1561-6.
23. Madrid AH, Bueno MG, Rebollo JMG, et al. 2002. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation, 106:331-6.
24. Mitchell GF, Vasan RS, Keyes MJ, et al. 2007. Pulse pressure and risk of new onset atrial fibrillation. JAMA, 297:709-15.
25. Maggioni AP, Latini R, Carson PE, et al. 2005. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J, 149:548-57.
26. Malmqvist K, Kahan T, Edner M, et al. 2000. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens, 19:1167-76.
27. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. 1997. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation, 95:1464-70.
28. Okin PM, Wacthell K, Devereux RB, et al. 2006. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA, 296:1242-8.
29. Perlini S, Muiesan ML, Cuspidi C, et al. 2001. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation, 103:678-83.
30. Reudelhuber TL, Bernstein KE, Delafontaine P. 2007. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension, 49:1196-201.
31. Rogg H, de Gasparo M, Graedel E, et al. 1996. Angiotensin II-receptor sybtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J, 17:1112-120.
32. Schlaich MP, Schobel H, Langenfeld MRV, et al. 1998. Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol, 49:153-9.
33. Schmieder RE. 2005. The role on non-haemodynamic factors in the genesis of LVH. Nephron Dial Transplant, 20:2610-12.
34. Schmieder RE, Langefeld MR, Friedrich A, et al. 1996. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation, 94:1304-9.
35. Schmieder RE, Messerli FH, Garavaglia GE, et al. 1988. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med, 84(Suppl A):136-39.
36. Schmieder RE, Martus P, Klingbeil AU. 1996. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA, 275:1507-13.
37. Schmieder RE, Schlaich MF, Klingbeil AU, et al. 1998. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1998). Nephrol Dial Transplant, 13:564-9.
38. Schmieder R, Kjeldsen SE, Julius S, et al. 2006. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial [abstract]. J Hypertens, 24:(Suppl)S3.
39. Schneider MP, Klingbeil AU, Delles C, et al. 2004. Effect of irbesartan versus atenolol on left ventricular mass and voltage. Results of the CardioVascular Irbesartan Project. Hypertension, 44:61-6.
40. Sega R, Trocino G, Lanzarotti A, et al. 2001. Alterations of cardiac structure in patients with isolated, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA]) Study. Circulation, 104:1385-92.
41. Trimarco B, De Luca N, Ricciardelli B, et al. 1988. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol, 62:745-50.
42. Tsai CT, Lai LP, Lin JL, et al. 2004. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation, 104:2608-14.
43. Verdecchia P, Porcellati C, Reboldi G, et al. 2001. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation, 104:2039-44.
44. Verdecchia P, Angeli F, Borgioni C, et al. 2003. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens, 16:895-9.
45. Verdecchia P, Reboldi G, Gattobigio R, et al. 2003. Atrial fibrillation in hypertension: predictors and outcome. Hypertension, 41:218-23.
46. Wachtell K, Lehto M, Gerdts E, et al. 2005. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol, 45:712-19.
47. Yasunari K, Maeda K, Watanabe T, et al. 2004. Comparative effects of valsartan versus amlodipine on left ventricular and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol, 43:2116-23.